2024
Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10+ Breg cells and protect against T1D
Yang X, Huang J, Peng J, Wang P, Wong F, Wang R, Wang D, Wen L. Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10+ Breg cells and protect against T1D. Frontiers In Immunology 2024, 15: 1413177. PMID: 38903498, PMCID: PMC11187306, DOI: 10.3389/fimmu.2024.1413177.Peer-Reviewed Original ResearchGut microbiotaGerm-free miceToll-like receptor 9Increased gut permeabilityIntestinal microbiotaGut permeabilityT1D developmentGut microbiota compositionFecal samplesTransferred to germ-free miceGut barrier integrityBreg cell differentiationMicrobiota influenceMucin degradationMicrobiota compositionBreg cellsAltered microbiotaMicrobiota impactMicrobiotaGene expressionImmune regulationDevelopment of T1DCell differentiationGutNOD miceTlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis
Wang P, Yang X, Zhang L, Sha S, Huang J, Peng J, Gu J, Pearson J, Hu Y, Zhao H, Wong F, Wang Q, Wen L. Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis. Nature Communications 2024, 15: 4232. PMID: 38762479, PMCID: PMC11102548, DOI: 10.1038/s41467-024-48611-8.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Gut microbiotaGut microbial communityTransferred to germ-free miceB cellsGerm-free miceTLR9 deficiencyKO miceGene sequencesGerminal center B cellsMicrobial communitiesMarginal zone B cellsGut dysbiosisFollicular helper cellsSelf-DNAMetabolic homeostasisAssociated with increased frequencyPro-inflammatory stateFat tissue inflammationGutHigh-fat dietMicrobiotaHelper cellsT cellsControl miceGut microbiota and therapy for obesity and type 2 diabetes
Zhang L, Wang P, Huang J, Xing Y, Wong F, Suo J, Wen L. Gut microbiota and therapy for obesity and type 2 diabetes. Frontiers In Endocrinology 2024, 15: 1333778. PMID: 38596222, PMCID: PMC11002083, DOI: 10.3389/fendo.2024.1333778.Peer-Reviewed Original ResearchGut microbiota compositionGut microbiotaMicrobiota compositionType 2 diabetesFunction of gut microbiotaHomeostasis of gut microbiotaMicrobiota-based approachesModulating gut microbiotaBariatric surgeryEffective anti-obesity treatmentQuality of life of individualsMicrobiotaMildly obese patientsSustained weight lossAssociated with obesityDiminished quality of lifeAnti-obesity treatmentObesity management strategiesGutQuality of lifeNon-surgical interventionsIncreased medical costsPublic health crisisMusculoskeletal disordersObese patients
2023
Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study
Hu J, Ding J, Li X, Li J, Zheng T, Xie L, Li C, Tang Y, Guo K, Huang J, Liu S, Yan J, Peng W, Hou C, Wen L, Xu A, Zhou Z, Xiao Y. Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study. EClinicalMedicine 2023, 62: 102132. PMID: 37593224, PMCID: PMC10430172, DOI: 10.1016/j.eclinm.2023.102132.Peer-Reviewed Original ResearchAdult-onset T1DHealthy controlsGut microbiotaT1D patientsShort-chain fatty acid-producing bacteriaPopulation-based cross-sectional studyGut microbial alterationsRecent epidemiological dataType 1 diabetesCross-sectional studyT2D patientsIntestinal disturbancesDifferential diagnosisSerum metabolitesEpidemiological dataPatientsStudy subjectsT1DDiabetesSignificant differencesAcid-producing bacteriaMicrobiotaMicrobial profilesNational Key ResearchMicrobial alterations
2020
Gut microbial metabolites alter IgA immunity in type 1 diabetes
Huang J, Pearson JA, Peng J, Hu Y, Sha S, Xing Y, Huang G, Li X, Hu F, Xie Z, Xiao Y, Luo S, Chao C, Wong F, Zhou Z, Wen L. Gut microbial metabolites alter IgA immunity in type 1 diabetes. JCI Insight 2020, 5 PMID: 32298241, PMCID: PMC7259536, DOI: 10.1172/jci.insight.135718.Peer-Reviewed Original ResearchConceptsType 1 diabetesGut microbiotaNOD miceImmune responseGerm-free NOD miceIgA immune responseIgA-mediated immunityHealthy control subjectsPotential therapeutic agentShort-chain fatty acid productionIgA immunityT1D preventionIgA responsesControl subjectsDecreased severityT1DTherapeutic agentsFunctional effectsMicrobiotaDiabetesPatientsUnderlying mechanismMiceImmunitySCFA